MAP4K1 Antibodies

Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1)

Serine/threonine-protein kinase, which might play a role in the response to environmental stress. Appears to act upstream of the JUN N-terminal pathway.

May play a role in hematopoietic lineage decisions and growth regulation. Able to autophosphorylate.

Gene Information

Human
Gene Name:	MAP4K1
Uniprot:	Q92918
Entrez:	11184

Family

Belongs to:
protein kinase superfamily

Alternative Names

EC 2.7.11; EC 2.7.11.1; Hematopoietic progenitor kinase; HPK1hematopoietic progenitor kinase 1; MAPK/ERK kinase kinase kinase 1; MEK kinase kinase 1; MEKKK 1; mitogen-activated protein kinase kinase kinase kinase 1

Molecular Weight

Mass (kDA):
91.296 kDA

Genomic Context

Human
Location:	19q13.2
Sequence:	19; NC_000019.10 (38587641..38617953, complement)

Tissue Specificity

Expressed primarily in hematopoietic organs, including bone marrow, spleen and thymus. Also expressed at very low levels in lung, kidney, mammary glands and small intestine.

Diseases

• Cell Invasion
• Malignant Neoplasms
• Neoplasms
• Cell Transformation, Neoplastic
• Colonic Neoplasms
• Malignant Tumor Of Colon
• Neoplasm Invasiveness
• Carcinoma
• Autoimmunity
• Bladder Neoplasm
• Adenocarcinoma
• Neoplasm Metastasis
• Cerebellar Neoplasms

• Tumor Progression
• Malignant Neoplasm Of Brain
• Malignant Paraganglionic Neoplasm
• Autoimmune Diseases
• Brain Neoplasms
• Malignant Neoplasm Of Urinary Bladder
• Autoimmune Reaction

Interacting Proteins

• ABL1
• CRK
• CRKL
• FYN
• GRB2

• NCK1
• PIK3R1
• PLCG1
• SLAMF1

Pathways

• Programmed Cell Death
• Cell Death
• Cell Migration
• Cell Proliferation
• Cell Cycle
• T Cell Proliferation
• Cell Development

• Oncogenesis

PTMs

• Phosphorylation
• Cleavage

• Methylation
• Ubiquitination

Research Areas

• Protein Kinase

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/MAP4K1

Best Uses Of The MAP4K1 Marker From Boster Bio

Boster Bio is the expert when it comes to validation and analysis of an antibody. This article will discuss the Anti-MAP4K1/HPK1 antibody by Boster Bio and its applications in cancer research. We will also discuss the validation and reference materials. These are the best uses that this antibody can be used for. Read on to discover more. MAP4K1 is an essential marker for cancer research, particularly in the field of immunology.

Boster Bio Anti–MAP4K1/HPK1 antibody

Boster Bio produces the anti-MAP4K1 antibody. This antibody reacts with Humans and Mouse. This boster bio antibody was purified using peptide affinity purification. It is also available as a bosterbio M07909 product. It has been tested against Rat, Mouse, and Human for WB applications. It has a high affinity against Mouse and Humans and is available in both stock forms and diluted form.

MAP4K1 promotes polyubiquitination TBK1/IKKe. This is stopped if MAP4K1 is knocked down. MAP4K1 plays a critical role in the regulation of ubiquitin levels in both the extracellular and cytoplasmic domains. Boster Bio Anti MAP4K1/HPK1 antibody targets this ubiquitin–protein complex to inhibit polyubiquitination.

Inheritance immunity plays a significant role in the function of MAP4K1. It is vital for IFN b production. In addition, it inhibits the activation of IRF3 and inhibits the production of IFN-I. It is an effective therapeutic target in the management of autoimmune diseases. So, it is highly recommended to use this anti-MAP4K1/HPK1 antibody in your research.

MAP4K1 regulates the RLR antiviral pathway at the TBK1/IKKe level. MAP4K1 deassembles the MAVS signalosome which promotes virus replication within the cell. MAP4K1 also suppresses IFN-b production and antiviral response. Its roles are multiple in the immune system.

Applications

MAP4K1 belongs to the mitogen-activated proteins kinase family. It is involved in the regulation of growth and development and may play a role in the response to environmental stress. It is also involved in hematopoietic lineage decisions. These are all possible uses for the MAP4K1 indicator. However, further research is needed to confirm these hypotheses.

MAP4K1 is also known as HPK1, a member of the Ste20 serine/threonine kinase superfamily. It acts as a tissue-specific upstream activator of the MEKK/JNK/SAPK signaling pathway. It suppresses TCR signaling activity and thereby inhibits T cell proliferation. MAP4K1 phosphorylates adaptor protein SLP-76, a molecule involved in T cell signaling. It was first expressed in insect cells that had an N-terminal GST tag.

Validation

The current study investigated the relationship between MAP4K1 transcript and overall survival (OS). OS is the time between diagnosis and withdrawal or death. Relapse-free survival (RFS), is the time period without relapse following treatment. The MAP4K1 expression level was not related to age, sex, bone marrow blasts, and hemoglobin levels.

To confirm a connection between MAP4K1 expression levels and patient outcomes, researchers used an immunodeficient mouse model to examine the role of this protein in AML. The researchers administered THP-1Luc cells to 15 mice. The tumor burden was observed for 4 weeks. The percentages of human CD45+ cell were also determined. The study showed that MAP4K1 plays a role in pro-leukemia.

HHT-induced resistant AML cell line lines showed high levels of the MAP4K1 marker. Overexpression of this gene predicted poor patient outcomes. MAP4K1 also played a mediator in HHT resistance. This gene is a promising target to develop treatments for resistant AML. This study aims to identify novel treatments and understand MAP4K1’s regulatory systems. It is therefore essential to study the MAP4K1 gene within AML.

The independent prognostic marker MAP4K1 has been shown to be a reliable marker for AML. It is a potential therapeutic target, which could improve the effectiveness and efficacy of HHT as well as other agents against drug-resistant AML. To understand the mechanisms behind drug resistance in AML, further research is needed. Researchers can then develop effective drugs to combat drug-resistant AML once they have this information. This study can help determine if HHT or Sunitinib treatments will increase patient survival.

References

Numerous studies have shown a link between MAP4K1 and the progression of cancer. The progression of colon cancer was reduced by inhibiting MAP4K1, while patients with ER+ idc experienced a longer overall life expectancy. However, no studies have been done to examine the role that MAP4K1 plays in AML. To understand the mechanisms that underlie this gene's disease activity, further research is required.